FASN and lung carcinoma: EGCG anti-cancer effects in lung cancer have also been evidenced and, besides FASN-inhibition, several mechanisms of action have been proposed, such as G3BP1 (GTPase activating protein (SH3 domain) binding protein) inhibition [29], generation of Reactive Oxygen Species (ROS) [30] or induction of p53-dependent transcription [31].